Comparison of effectiveness between polaprezinc and Zinc acetate hydrate on hypozincemia in hemodialysis patients.

A randomized controlled non-blinded trial for Comparison of effectiveness between polaprezinc and Zinc acetate hydrate on hypozincemia in hemodialysis patients. - EPZA

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000038759

Enrollment

Registered

2019-12-31

Start date

2019-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Zinc deficiency

Interventions

Zinc acetate hydrate(25mg/Tb) 1 tablet twice a day for 6 months. Polaprezink(75mg/Tb) 1 tablet twice a day for 6 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who undergo hemodialysis 3times a week for 2years or more Patients whose blood zinc concentration before dialysis is less than 60microg/dL Patients with written consent

Exclusion criteria

Exclusion criteria: Patient after enterectomy Patients with peritoneal dialysis Pregnant or breastfeeding Patients allergic to zinc acetate hydrate or polaprezinc Patients who are unable to carry out contraindications or contraception during the study period Patients who are difficult to take orally Patients with serum copper less than 30microg/dL Patients judged to be inappropriate for inclusion in the study by the principal investigator

Design outcomes

Primary

Measure	Time frame
Efficacy and safety for 6 months from the start of administration.	—

Secondary

Measure	Time frame
copper deficiency	—

Countries

Japan

Contacts

Public Contactkoh hirasawa

Kenwakai Hospital hemodialysis center

k-hirasawa@kenwakai.or.jp0265233116

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026